---
title: "Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer"
description: "This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progressi"
url: "https://www.clareohealth.com/clinical-trials/NCT07250477"
---

This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.

## Key Facts

**ID:** NCT07250477
**Status:** RECRUITING
**Phase:** PHASE2
**Type:** INTERVENTIONAL
**Enrollment:** 56
**Sponsor:** University of California, Davis

## About This Study

This clinical trial is testing a new approach to treat advanced non-small cell lung cancer (NSCLC) using a personalized treatment plan based on specific assessments. It is for adults with previously untreated stage IIIC or IV NSCLC, which means their cancer is either advanced or cannot be surgically removed.

## Detailed Description

Participants will be randomized to an intervention arm or a standard of care (SOC) arm. Participants in the intervention arm will undergo pretreatment assessment with PROphet Clinical Benefit (CB) and the Cancer and Aging Research Group Toxicity Tool (CARG-TT); data from the assessments will be used to select systemic therapy, which can be any SOC treatment that incorporates a Programmed death-ligand 1 (PD-(L)1) antibody with or without chemotherapy and/or with or without Cytotoxic T-lymphocyte associated protein 4 (CTLA4) antibody. Participants in the SOC arm will undergo SOC biomarker assessment and subsequent selection of SOC systemic therapy. The primary endpoint is 12-month progression free survival (PFS). The findings will be stratified according to participant performance status and tumor PD-L1 score. The hypothesis is that risk-adapted, proteomic-guided systemic therapy will improve PFS among patients with previously untreated advanced NSCLC compared to SOC systemic therapy.

## Conditions

- Non-small Cell Lung Cancer Stage IIIC
- Non-small Cell Lung Cancer Stage IV
- Non Small Cell Lung Cancer
- Non-small Cell Lung Cancer Metastatic
- Non-small Cell Lung Cancer Unresectable

## Interventions

**DRUG: Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.**
Pretreatment assessment with PROphet CB and CARG-TT, which will be used to determine which first-line systemic treatment participants in the intervention arm receive. Systemic treatment will be pre-determined by the trial, according to the results from PROphet CB and CARG-TT.

**DRUG: Standard of Care**
Standard of care (SOC) biomarker testing followed by first-line treatment with either anti-PD(L)1 Immune checkpoint inhibitor (ICI) monotherapy or anti-PD(L)1 ICI + chemotherapy.

## Eligibility

Inclusion Criteria: * Participants must have histologically confirmed non-small cell lung cancer that is metastatic or unresectable (stage IIIC or IV), deemed appropriate to recei…

## Who Can Participate

**Minimum age:** 18

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Enloe Health Regional Cancer Center, Chico, California, United States
- Rideout Cancer Center, Marysville, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Tahoe Forest Cancer Center, Truckee, California, United States

## Contact Information

**Office of Clinical Research**
Email: OCRReferral@health.ucdavis.edu
Phone: (916) 734-3772

## Important Dates

**Study start:** January 30, 2026

**Completion date:** December 1, 2036

**Last updated:** August 25, 2026

## Collaborators

- National Cancer Institute (NCI)

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have advanced non-small cell lung cancer that is either stage IIIC or IV.
- You are looking for a personalized treatment plan based on specific assessments.
- You have not received any previous systemic therapy for your advanced lung cancer.

### Questions to Ask

- What specific assessments will be done to determine my treatment?
- How does the new treatment compare to the standard options available?
- What are the potential side effects of the treatments I might receive?
- How often will I need to come in for visits during the trial?
- What happens if my cancer progresses while I'm in the trial?
- Are there any additional costs or travel requirements I should be aware of?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07250477)
